Catherine Vézina

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren et al. · The Lancet Oncology · 2019 · 343 citations

Medicine, Oncology, Pharmacotherapy +17

Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas

Karine Jacob, Dongh-Anh Quang-Khuong, David Jones et al. · Clinical Cancer Research · 2011 · 174 citations · Full text

Medicine, Genetics, Oncology +17

Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study

Sheena Mukkada, Nickhill Bhakta, Guillermo Chantada et al. · The Lancet Oncology · 2021 · 134 citations · Full text

Medicine, Oncology, Pediatrics +15

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010

Catherine Vézina, Manuel Carção, Claire Infante‐Rivard et al. · Haemophilia · 2014 · 31 citations

Medicine, Hematology, Clinical Epidemiology +10

Alloantibody developed in a factor XIII A subunit deficient patient during substitution therapy; characterization of the antibody

Krisztina Pénzes, Catherine Vézina, Zsuzsanna Bereczky et al. · Haemophilia · 2015 · 18 citations · Full text

Life Sciences, Hematology, Molecular Biology +13